Longeveron is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Its lead investigational product is Lomecel-B™, which is derived from the bone marrow of young healthy adult donors.

The company believes that by using the same cells that promote tissue repair, organ maintenance and immune system function, it can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging.